Role of thalidomide in previously untreated patients with multiple myeloma. - Wikidata - awgldk - TriplyDB

Role of thalidomide in previously untreated patients with multiple myeloma.

Role of thalidomide in previously untreated patients with multiple myeloma.

http://www.wikidata.org/entity/Q37300004

about

The Eltrombopag antitumor effect on hepatocellular carcinoma.Dilemmas in treating smoldering multiple myeloma.Concise asymmetric synthesis of configurationally stable 4-trifluoromethyl thalidomide.

P2860

Q33426135-043C7CE4-BD76-4B4B-B7EF-014FA6C62B2D Q34716500-3D8FCCF9-61BB-48AA-B299-B9BEC9A31685 Q39959248-2AE07CDE-D840-4DDF-8D93-303418C3F186

P2860

Role of thalidomide in previously untreated patients with multiple myeloma.

http://www.wikidata.org/entity/Q37300004

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on October 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Role of thalidomide in previously untreated patients with multiple myeloma.

@en

Role of thalidomide in previously untreated patients with multiple myeloma.

@nl

type

label

Role of thalidomide in previously untreated patients with multiple myeloma.

@en

Role of thalidomide in previously untreated patients with multiple myeloma.

@nl

prefLabel

Role of thalidomide in previously untreated patients with multiple myeloma.

@en

Role of thalidomide in previously untreated patients with multiple myeloma.

@nl

P1433

Q37300004-793E5D32-96FC-426A-8332-F6CE8E067C17

P1476

Q37300004-7A434384-D464-45D7-B876-B1FFA62D1351

P2093

Q37300004-1D173600-5D81-4A98-8C8A-BDDD2F5FA575

Q37300004-4971A614-3CEC-441F-AE00-0FC1BA17672F

Q37300004-94ADC24D-016D-476C-BD14-2E2B3EEB46BA

Q37300004-C39E4118-7C7B-47B1-BE97-5AD91C42F075

Q37300004-F990BE57-9BB0-4564-81D9-F23EC82D6591

Q37300004-FC4DB808-DF2D-4DD0-A73D-4E029304CA5D

P2860

Q37300004-014356C7-4710-471C-B651-B01728BAE6BD

Q37300004-06E4EAC3-8617-4741-A28D-DB56801E34C0

Q37300004-08384F2D-2C67-468E-BB7C-0B2BBAB15A40

Q37300004-0A3BB227-B963-4A25-A01F-D0D9B94A6EE2

Q37300004-0CE12784-5D17-4253-BA10-EB4C84A447CD

Q37300004-10EDC944-1D4F-428C-9756-248A7928D0E2

Q37300004-1D06ED4B-37BD-4BA1-87AE-9CFD700FD5CD

Q37300004-3503DB0B-BEA3-4A3A-B9DC-142BF2AA851A

Q37300004-387A99E0-9F3F-488D-956B-7FF80C521CF6

Q37300004-4289EB75-5FA7-4005-97CA-06F256D42A56

P304

Q37300004-3184C013-946F-413C-997F-96DEFE92DBDC

P31

Q37300004-9FFCA317-FC53-499A-A98D-9A427C2F1A44

P356

Q37300004-27CF9B7D-48E9-4520-8421-44BB9E4D986F

P433

Q37300004-302BFBCC-ECD5-4EB8-AEED-88190B285983

P478

Q37300004-1D9E9900-8E79-42D2-B755-76B9462A3E48

P50

Q37300004-27127498-FD50-4A29-A70C-A56BA4C09F17

Q37300004-4691E370-9899-4975-837F-8E09F5BC80E8

Q37300004-5D71A230-AB8B-4C06-A80D-5E161E40A660

Q37300004-8E27FCED-ACC1-414D-848F-AE81D7E8630C

Q37300004-94B054C8-25B9-44EF-AB67-15CB9D4CE75D

Q37300004-A3AAED18-5197-4DE3-A4D2-EC7664B60611

P577

Q37300004-D861C1E0-B5AC-4A1C-83A1-4A181A91E54F

P698

Q37300004-9ACEB40C-1D68-4CA2-BF7C-5CB00E263E95

P921

Q37300004-220E1240-8829-4177-95FA-8EABFAEB2554

P356

14737140.8.10.1569

P1433

Expert Review of Anticancer Therapy

P1476

Role of thalidomide in previously untreated patients with multiple myeloma

@en

P2093

Fortunato Morabito

http://www.w3.org/2001/XMLSchema#string

Giuseppe Pietrantuono

http://www.w3.org/2001/XMLSchema#string

Gruppo Italiano Malatte Ematologiche dell'Adulto Multiple Myeloma Working Party

http://www.w3.org/2001/XMLSchema#string

Italian Myeloma Network and Gruppo Italiano Studio Linfomi

http://www.w3.org/2001/XMLSchema#string

Mario Boccadoro

http://www.w3.org/2001/XMLSchema#string

Sara Bringhen

http://www.w3.org/2001/XMLSchema#string

P2860

Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study.

Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma.

A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma.

Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma.

Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1.

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.

P304

1569-1580

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14737140.8.10.1569

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Francesco Di Raimondo

Pellegrino Musto

Fiorella D'Auria

Antonio Palumbo

P577

2008-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18925849

http://www.w3.org/2001/XMLSchema#string

P921